Michael J. Purcell
CIK 1694934 · last filed 2026-10-27
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
TRHC price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
BROOMALL, PA 19008
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Hepion Pharmaceuticals, Inc. (HEPA) Delisted | Director | 3,250,000 | $0.08 | $260.0K | $100.0K | 4 | 2026-10-27 |
| IMXI | Director | 99,918 | $7.57 | $756.4K | $105.5K | 34 | 2026-10-02 |
| Tabula Rasa HealthCare, Inc. (TRHC) Delisted | Director | 139,322 | $10.50 | $1.46M | $289.0K | 13 | 2023-06-13 |
| International Money Express, Inc. (IMXIW) Delisted | Director | 7,063 | — | — | $0 | 1 | 2018-07-30 |
| PN | Director | 1,237 | $2.34 | $2.9K | $0 | 1 | 2017-01-25 |
Recent Filings · Page 2 of 6
55 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-07-03 | IMXI | Grant (A) | +1,482 | $15.6K | EDGAR |
| 2025-06-24 | IMXI | Grant (A) | +14,867 | $150.0K | EDGAR |
| 2025-04-03 | IMXI | Grant (A) | +1,223 | $15.6K | EDGAR |
| 2025-01-03 | IMXI | Grant (A) | +750 | $15.6K | EDGAR |
| 2024-10-03 | IMXI | Grant (A) | +889 | $15.6K | EDGAR |
| 2024-07-29 | IMXI | Grant (A) | +238 | $5.0K | EDGAR |
| 2024-07-03 | IMXI | Grant (A) | +771 | $15.6K | EDGAR |
| 2024-06-26 | IMXI | Grant (A) | +7,098 | $145.0K | EDGAR |
| 2024-04-02 | IMXI | Grant (A) | +1,384 | $0 | EDGAR |
| 2024-03-07 | Hepion Pharmaceuticals, Inc. (HEPA) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.